WEKO3
アイテム
遺伝子治療 : 現状と将来
http://hdl.handle.net/10191/42631
http://hdl.handle.net/10191/4263146ab8d69-8156-4308-ba54-ff52ffc158dd
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
109(9-10)_413-417.pdf (1.0 MB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-07-15 | |||||
| タイトル | ||||||
| タイトル | 遺伝子治療 : 現状と将来 | |||||
| タイトル | ||||||
| タイトル | 遺伝子治療 : 現状と将来 | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | gene therapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ADA deficiency | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | vectors | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 遺伝子治療 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ADA 欠損症 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ベクター | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| その他のタイトル | ||||||
| その他のタイトル | Gene Therapy : Present State and Future Aspect | |||||
| 著者 |
高久, 史麿
× 高久, 史麿 |
|||||
| 著者別名 | ||||||
| 識別子Scheme | WEKO | |||||
| 識別子 | 115292 | |||||
| 姓名 | Takaku, Fumimaro | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Gene therapy is defined as a procedure to introduce genes or gene-transduced cells into our body with the purpose of treatment of diseases. Gene therapy had started in USA in 1989, and at this moment, more 100 protocols have been approved by the Recombinant DNA advisory committee in NIH, and about 600 patients have been subjected to the clinical trial of these gene therapies. Although the efficacy of gene therapies is not clear in most of them, some gene therapies such as therapy for congenital deficiency of ADA has been reported to be very effective. In our country, the guide line for gene therapy was made by Ministry of Health and Welfare (MHW) in 1993, and the members of Central Committee to evaluate the protocol of gene therapy were appointed by MHW in 1994. The first gene therapy in our country had been started by the pediatricians in Hokkaido University on a boy with a congenital ADA deficiency in August 1995, with vectors supplied from GTI company in USA. To promote the gene therapy in Japan, it is necessary to encourage companies to join the business of making new vectors for gene therapy and to establish the system to evaluate the efficacy and safety of these vectors. | |||||
| 書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 109, 号 9-10, p. 413-417, 発行日 1995-10 |
|||||
| 出版者 | ||||||
| 出版者 | 新潟医学会 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00290440 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00182415 | |||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
